← All trials
NCT04681027
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 11, 2013
- Primary completion
- Apr 4, 2017
- Completion date
- Jan 31, 2021
- First posted
- Dec 23, 2020
- Last posted
- Dec 23, 2020
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Endo PharmaceuticalsLead sponsor
- Endo PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.